Evercore ISI Group Maintains In-Line on Moderna, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Cory Kasimov maintains an In-Line rating on Moderna (NASDAQ:MRNA) and keeps the price target at $120.
June 27, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Evercore ISI Group analyst Cory Kasimov maintains an In-Line rating on Moderna and keeps the price target at $120.
The maintenance of an In-Line rating and a $120 price target suggests that the analyst sees no significant short-term changes in Moderna's stock price. This neutral stance is likely to result in minimal immediate impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100